News
Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G protein-coupled receptors (GPCRs).
Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...
Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...
While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...
Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback